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Adaptive combination of Bayes 
factors as a powerful method 
for the joint analysis of rare and 
common variants
Wan-Yu Lin1,2, Wei J. Chen  1,2,3,4, Chih-Min Liu5, Hai-Gwo Hwu  1,5, Steven A. McCarroll6,7,8, 
Stephen J. Glatt9 & Ming T. Tsuang10,11
Multi-marker association tests can be more powerful than single-locus analyses because they 
aggregate the variant information within a gene/region. However, combining the association signals 
of multiple markers within a gene/region may cause noise due to the inclusion of neutral variants, 
which usually compromises the power of a test. To reduce noise, the “adaptive combination of P-
values” (ADA) method removes variants with larger P-values. However, when both rare and common 
variants are considered, it is not optimal to truncate variants according to their P-values. An alternative 
summary measure, the Bayes factor (BF), is defined as the ratio of the probability of the data under 
the alternative hypothesis to that under the null hypothesis. The BF quantifies the “relative” evidence 
supporting the alternative hypothesis. Here, we propose an “adaptive combination of Bayes factors” 
(ADABF) method that can be directly applied to variants with a wide spectrum of minor allele 
frequencies. The simulations show that ADABF is more powerful than single-nucleotide polymorphism 
(SNP)-set kernel association tests and burden tests. We also analyzed 1,109 case-parent trios from the 
Schizophrenia Trio Genomic Research in Taiwan. Three genes on chromosome 19p13.2 were found to be 
associated with schizophrenia at the suggestive significance level of 5 × 10−5.
Multi-marker association tests can be more powerful than single-locus analyses because these tests combine 
variant information within a gene/region. Moreover, the multiple-testing penalty is moderate compared with that 
encountered in single-locus analyses. However, combining the association signals of multiple markers within a 
gene/region may cause noise due to the inclusion of neutral variants, which usually compromises the power of a 
multi-marker association test. To eliminate noise from neutral variants, the “adaptive combination of P-values” 
(ADA) method was proposed for the analyses of unrelated subjects1,2 and family data3.
The ADA method was originally proposed for rare-variant association testing2. While “rare” is frequently 
defined arbitrarily, here, according to Ionita-Laza et al.4, we defined variants with a minor allele frequency (MAF) 
< n1/ 2  as rare, where n is the number of individuals in the study. The per-site P-values were first calculated for 
each individual variant site, and the ADA method was used to truncate larger per-site P-values that were more 
likely to be attributed to neutral variants. The P-value is the probability of obtaining a statistic as extreme as or 
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more extreme than the observed statistic under the null hypothesis (H0) of no association. However, a P-value 
provides no information regarding the alternative hypothesis (H1). For example, a P-value of 10−9 may appear to 
provide strong evidence against H0; however, if the test is low-powered, it may be almost as unlikely under H1 as 
under H05–7. In genome-wide association studies (GWAS), the power to detect disease-associated 
single-nucleotide polymorphisms (SNPs) varies with MAFs. In this work, we show that truncating variants 
according to P-values is not optimal, when both rare and common variants are considered (see the subsection 
“Ranking by Bayes factor vs. P-value”).
Zhou and Wang8 have extended the ADA method to address both rare and common variants (namely, 
RC-ADA, or “rare and common variants by adaptive combination of P-values”). However, the RC-ADA method 
also truncates neutral variants according to their P-values. In RC-ADA8, rare variants and common variants are 
weighted according to Beta(MAF;1,25) and Beta(MAF;0.5,0.5)4, respectively, where MAF is the MAF of the con-
sidered SNP. Compared with the commonly used weight function Beta(MAF;1,25), Beta(MAF;0.5,0.5) decreases 
slowly as the MAF increases. RC-ADA preserves the associations of common variants by assigning them this 
weight function.
An alternative summary measure to the P-value is the Bayes factor (BF)9,10, which is the ratio of the probability 
of the data under the alternative hypothesis to that under the null hypothesis, as follows:
=
|
|
BF Data H
Data H
Pr( )
Pr( )
,
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1
0
where H1 and H0 are the alternative hypothesis and the null hypothesis, respectively. In this work, we show that 
truncating variants according to BFs is superior to truncating variants according to P-values, because BFs quan-
tify the “relative” evidence supporting H1. Here, we propose an adaptive combination of BFs (ADABF) method 
by extending our previous ADA method2 and the “adaptive rank truncated product” (ARTP) method11,12. As 
described in the “Methods” section, the highest k BFs in favor of H1 are combined, in the observed sample and 
in each of the resamples, respectively. The optimal k that achieves the strongest signal is allowed to vary in the 
observed sample and in each of the resamples. Then, the significance of the gene/region is assessed by comparing 
the strongest signal in the observed sample with its counterparts in the resampling replicates.
The logic underlying this work can be traced back to the “variable-threshold (VT)” approach13. In the VT 
approach, Price et al. assume that a certain unknown MAF threshold, T, exists, and variants with MAFs lower 
than T are more likely to be disease-associated. Therefore, they compute the statistic for each MAF threshold 
and then search for the optimal MAF threshold with permutations. However, the MAF has little relevance to the 
association signals14,15. Disease-associated variants can be either rare or common. Here, we propose the ADABF 
method, which is based on the concept of VT, but we assume that a certain unknown BF threshold exists, and 
variants with BFs larger than this threshold are more likely to be disease-associated.
By performing extensive simulations with case-parent trios and unrelated case-control data, we find that our 
ADABF test is valid because the type I error rates match the nominal significance levels. Moreover, the ADABF 
test is more powerful than the other gene-based tests16–19. Various multi-marker methods and the single-locus 
transmission disequilibrium test (TDT)20,21 were then applied to the empirical data from the Schizophrenia Trio 
Genomic Research in Taiwan (S-TOGET)22.
Results
Simulation Results. Table 1 provides the type I error rates observed in 1,000,000 simulation replications 
(10,000 replications performed for each of the 100 Cosi data sets). All five tests are valid because their type I error 
rates match the nominal significance levels. Figures 1 (for case-parent trios) and 2 (for unrelated case-control 
data) present the power given the genome-wide significance level of 2.5 × 10−6 (= .0 05/20000, corresponding to a 
Bonferroni correction for testing 20,000 independent genes23,24). The power for each scenario was evaluated using 
10,000 simulation replicates (100 replicates for each Cosi data set). The ADABF method outperformed the other 
multi-marker tests because it excluded the variants with smaller BFs.
As described in the “Methods” section, we created the “ADABF1” test representing our ADABF method cou-
pled with another prior distribution. While the prior used in ADABF was chosen according to the WTCCC 
GWAS6, the purpose of adding ADABF1 was to evaluate the sensitivity of the results to the prior setting. ADABF1 
(standard deviation of the prior distribution = 0.1) performed similarly to ADABF (standard deviation of the 
prior distribution = 0.2, following the WTCCC GWAS6). ADA also performed well because it truncated the 
Significance level ADABF ADABF1 ADA TK TLC
2,000 case-parent trios
α = 0.05 0.05012 0.05023 0.05041 0.05099 0.05062
α = 0.01 0.00919 0.00925 0.00908 0.01033 0.01016
α = 2.5 × 10−6 2 × 10−6 10−6 10−6 10−6 2 × 10−6
1,000 unrelated cases and 1,000 unrelated controls
α = 0.05 0.04999 0.04999 0.04785 0.04983 0.05030
α = 0.01 0.00915 0.00919 0.00879 0.00994 0.01017
α = 2.5 × 10−6 2 × 10−6 3 × 10−6 2 × 10−6 10−6 2 × 10−6
Table 1. Type I error rates in 1,000,000 simulation replications.
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variants with larger P-values. The popular kernel test (denoted by “TK”) was more powerful than the burden test 
(or linear combination test, denoted by “TLC”). Because the percentage of causal variants (2/150 or 4/150, as 
described in “Simulation Study”) was not large, TK was generally more powerful than TLC. This result is consist-
ent with the finding observed in rare-variant association testing for unrelated case-control data25.
Table 2 provides the average computation time (in seconds) for each test in our simulations, which was meas-
ured on a Linux platform with an Intel Xeon E5-2690 2.9 GHz processor and 8 GB memory. As described in the 
“Methods” section, we used the sequential resampling approach26 to compute the P-values of ADABF, ADABF1, 
and ADA. The minimum and maximum resampling numbers were set as 102 and 107, respectively. A longer time 
Figure 1. Simulation results of the case-parent trios. Top row: OR = 1.5 for a deleterious allele and OR = 0.67 
for a protective allele; bottom row: OR = 1.25 for a deleterious allele and OR = 0.8 for a protective allele. Left 
column: all causal variants were deleterious; right column: ~50% of the causal variants were deleterious and 
the other ~50% were protective. The x-axis shows the number of causal variants, whereas the y-axis shows the 
power (given a significance level of 2.5 × 10−6).
Number of causal variants ADABF* ADABF1* ADA* TK TLC
2000 case-parent trios
0 0.313 0.312 0.318
2.665 2.2902 56.225 55.136 52.148
4 89.127 88.149 85.243
1,000 unrelated cases and 1,000 unrelated controls
0 0.128 0.127 0.125
0.086 0.0842 36.572 35.581 33.236
4 64.145 64.132 63.259
Table 2. Average computation time (in seconds) for each test in our simulations. *We used the sequential 
resampling approach26 to compute the significance for ADABF, ADABF1, and ADA. The minimum and 
maximum numbers of resampling were set to be 102 and 107, respectively.
www.nature.com/scientificreports/
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Trait
Analysis 
gene
Causal 
percentage1
No. of common 
causal variants (MAF 
and effect size)2
The mean 
effect size 
of causal 
variants3
Rejection 
rates4 ADABF ADABF1 ADA TK TLC VW-TOW
Q4 All 3205 genes 0 0 0
Type I error 
rates 1.7 × 10
−5 1.7 × 10−5 1.9 × 10−5 1.0 × 10−4 1.1 × 10−4 1.2 × 10−5
Q1
KDR = .10/16 62 5% 1 (MAF = 16.5%, β = 0.15) β  = 0.60
Power
0.915 0.845 0.955 0.525 0.965 0.940
FLT1 11/35 31 4%= .
2 (MAF = 6.7%, 
β = 0.65); 
(MAF = 2.8%, 
β = 0.62)
β  = 0.51 1.000 1.000 1.000 0.975 0.815 1.000
HIF1A =4/8 50% 0 β  = 0.26 0.130 0.130 0.080 0.180 0.090 0.000
Summation of the power for KDR, FLT1, and HIF1A 2.045 1.975 2.035 1.680 1.870 1.940
Table 3. Rejection rates when analyzing Q4 (no causal variants exist) and Q1 (causal variants exist) in the GAW 
17 data 1Causal percentage = #(causal variants)/#(total variants). 2Following Ionita-Laza et al.4, here, we define 
variants with MAF ≥ = × = .n1/ 2 1/ 2 697 2 678% as common, where n = 697 is the sample size in the 
GAW 17 data. The effect size, β, is the displacement in mean levels of Q1 for each copy of the minor allele27. 3β  
is the arithmetic mean of the β’s for the causal variants in the gene. 4The rejection rates given the significance 
level = . = . × −0 05/3205 1 56 10 5, where 3205 is the number of genes in the GAW 17 data set. When analyzing 
Q4, in which no causal variants were simulated, the rejection rates were type I error rates. When analyzing Q1, 
which was influenced by certain causal variants, the rejection rates represented power.
Figure 2. Simulation results of the unrelated cases and controls. Top row: OR = 1.5 for a deleterious allele and 
OR = 0.67 for a protective allele; bottom row: OR = 1.25 for a deleterious allele and OR = 0.8 for a protective 
allele. Left column: all causal variants were deleterious; right column: ~50% of the causal variants were 
deleterious and the other ~50% were protective. The x-axis shows the number of causal variants, whereas the y-
axis shows the power (given a significance level of 2.5 × 10−6).
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would be required to obtain a more significant result. Therefore, the average computation time increased as the 
power and the number of causal variants increased.
For unrelated case-control data, we also evaluated the “Variable Weight Test for testing the effect of an 
Optimally Weighted combination of variants” (VW-TOW)18. Because this test requires permutations to compute 
the P-values, we could not afford the computation time to evaluate it under the genome-wide significance level of 
2.5 × 10−6 (= .0 05/20000). Instead, we performed VW-TOW with 10,000 permutations and evaluated its power 
under the significance level of 0.01 (as shown in Figure S1). We found that its power performance was similar to 
that of TK. Zhou and Wang showed that ADA2 was more powerful than VW-TOW18 in testing the effects of both 
rare and common variants and rare variants alone8. Because ADABF is based on a similar concept in which the 
neutral variants are removed, it is not surprising that this method can outperform VW-TOW18.
When the haplotypes were generated according to the linkage disequilibrium (LD) patterns in Asians, the sim-
ulation results were similar to the abovementioned findings (Figures S2-S4 in our supplementary information).
Application of Tests to the Genetic Analysis Workshop 17 Simulated Data. We further applied 
these multi-marker association tests to the Genetic Analysis Workshop 17 (GAW 17) simulated exome data27. 
Here, we analyzed two quantitative traits, i.e., Q4 and Q1. Q4 was not associated with any variants, whereas Q1 
was influenced by 39 variants located in nine genes27. Conditional on the genotype data, the trait simulations were 
performed 200 times to generate 200 replicates for the 697 unrelated individuals.
TLC and TK were performed using the “SKAT” R package (version 1.2.1)4,19,28. The “Davies” method was used 
to compute the P-values29. VW-TOW was implemented using the R code downloaded from the authors’ website, 
i.e., http://www.math.mtu.edu/~shuzhang/software.html, and the number of permutations was set as 106. The 
rare variant threshold (RVT) used in VW-TOW was set as n1/ 2 , where n is the sample size (697). Age and smok-
ing status served as covariates adjusted in TLC, TK, and VW-TOW.
To perform ADABF, ADABF1, and ADA2, we first considered the linear regression for each locus as follows:
β β β β= + + +E Y G Age Smoking( ) , (2)l l A S0
where Y is the quantitative trait (Q4 or Q1) and Gl is the genotype score (0, 1, or 2) of the lth variant (l = 1, …, 
24487). We obtained the maximum likelihood estimate (MLE) of βl (l = 1, …, 24487) and the corresponding 
variance by fitting the linear regression (Eq. 2). The prior distribution of the true effect sizes (βl’s) was assumed 
to be N(0,W), where the prior variance was W = 0.22 = 0.04 for ADABF and W = 0.12 = 0.01 for ADABF1 (see 
Figure S5). The prior for ADABF was the prior setting from the WTCCC GWAS6, and was adopted for ADABF 
throughout this work. Although this prior was originally proposed for dichotomous traits6, we considered it suit-
able for standardized quantitative traits with a mean of 0 and a standard deviation of 1 (because this prior implied 
that 95% of the true effect sizes range from −0.4 to 0.4).
The P-values of ADABF, ADABF1, and ADA2 were all obtained using the sequential resampling approach26 in 
which the minimum and maximum numbers of resampling were set as 102 and 107, respectively.
To assess the type I error rates, for each replication, we sequentially tested the association of each gene with 
Q4. Summarizing 200 replications, we obtained 641,000 (= 200 × 3205) P-values for each multi-marker associa-
tion method. Because Q4 did not depend on any variant, we assessed the type I error rates by calculating the 
percentages of the 641,000 P-values that were smaller than the significance level, i.e., 0 05/3205 1 56 10 5. = . × − , 
where 3,205 was the number of genes in the GAW 17 data. The first row in Table 3 provides the type I error rates. 
VW-TOW, ADABF, and ADABF1 yielded type I error rates that were the closest to the significance level 
(0 05/3205 1 56 10 5. = . × − ).
To quantify the power, we analyzed the association of all the nine causal genes that influenced Q127. Among 
the nine genes, the power for six genes (ARNT, ELAVL4, FLT4, HIF3A, VEGFA, and VEGFC) was smaller than 0.1 
for all the tests and it was impossible to compare the different methods using this very low power. The second to 
fourth rows shown in Table 3 provide the power for the remaining three causal genes, i.e., KDR, FLT1, and HIF1A, 
respectively. For each gene and each method, we obtained 200 P-values after analyzing all the 200 replicates. We 
quantified the power by calculating the percentage of the 200 P-values that were smaller than the significance 
level ( . = . × −0 05/3205 1 56 10 5, where 3,205 was the number of genes in the GAW 17 exome data).
Overall, ADABF was the most powerful test. It provided the largest summation of power for detecting the 
three genes. Different from the above simulation results, TLC was not the least powerful test for the following 
two reasons:
 (1) According to the simulation model of the GAW 17 data, for all causal variants, the minor allele was 
associated with a higher mean Q127. Therefore, the power of TLC would not be compromised due to the 
coexistence of trait-increasing and trait-decreasing variants.
 (2) As described in the above simulation results, TLC is vulnerable to a small causal percentage (i.e., the 
percentage of causal variants among all variants in the gene). In contrast to the small causal percentage in 
the abovementioned simulations (2/150 or 4/150), the causal percentages of the three genes were all larger 
than 30% here (shown in Table 3).
Application to the Schizophrenia Trio Genomic Research in Taiwan (S-TOGET). Schizophrenia 
is a highly heritable disease30. Previous studies have suggested that 1/3 to 1/2 of the genetic variants responsible 
for schizophrenia are common31,32, and these variants are genotyped using GWAS arrays. Therefore, GWAS is an 
important tool for exploring the genetic architecture of schizophrenia.
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A portion of the Taiwanese case-parent trios obtained from the S-TOGET from 2009 to 2014 were subjected 
to GWAS genotyping22, approved by the Research Ethics Committee of the National Taiwan University Hospital 
(NTUH-REC no. 200810016 R). We confirmed that all experiments were performed in accordance with the rel-
evant guidelines and regulations.
Totally 3,374 subjects were genotyped using the PsychChip array, which was developed by the Psychiatric 
Genomics Consortium (PGC) and Illumina (Illumina, San Diego, CA). After removing individuals with call 
rates < 98%, Mendelian errors, or sex inconsistency, 1,109 case-parent trios were used for analysis.
The PsychChip array (PsychChip_15048346_B) included ~580,000 markers in total. After removing invariant 
markers, markers with call rates < 98%, and markers that were significant for the Hardy-Weinberg equilibrium 
test (P-value < 10−6 in controls), 325,994 autosomal markers were retained for analysis.
The PsychChip array is a genotyping chip customized for psychiatric phenotypes. Unlike most commercial 
GWAS arrays, the PsychChip array allows investigators to simultaneously examine multiple genetic variants, 
including SNPs and rare variants. Of the 325,994 autosomal variants, 65,658 variants had MAFs < 1%, and 21,989 
variants had MAFs ranging from 1% to 5%, where the MAFs were calculated according to the parents of the 1,109 
trios.
We first used the single-variant TDT20,21 to analyze the 1,109 case-parent trios. As shown in the bottom-right 
plot of Fig. 3, no variant was found to be associated with schizophrenia at the genome-wide significance level of 
5 × 10−8 ( .0 05/1, 000, 000) or at the suggestive significance level of 10−6 (1/1, 000, 000)33,34.
We then resorted to multi-marker analyses. Because the SNP positions of the S-TOGET data were based on 
the human genome GRCh37/hg19 assembly, we mapped variants into genes according to the same assembly in 
the UCSC Genome Bioinformatics database (http://www.genome.ucsc.edu). We also included the 5’ and 3′ flank-
ing regions of each gene. The 5′ flanking region may contain regulatory sequences such as promoters that control 
gene transcription. The 3′ flanking region may contain sequences that terminate transcription. Multi-marker 
analyses may include ±5 kb35, ±10 kb36, ±20 kb37, or ±30 kb38 flanking regions of a gene. Because incorporating 
additional flanking sequences increases the coverage of more distant regulatory elements, we grouped the variants 
within ± 30 kb flanking regions of a gene into a multi-marker analysis according to Song et al.38. In total, there 
were 24,769 autosomal genes.
TLC and TK were performed using the “rvTDT” R package (version 1.0)16. ADABF, ADABF1, and ADA2 were 
performed using the sequential resampling approach26, in which the minimum and maximum numbers of resa-
mpling were set as 102 and 107, respectively. The genome-wide significance level for the gene-based analyses is 
usually determined at 2.5 × 10−6 ( .0 05/20, 000)23,24, and the suggestive significance level is set at 5 × 10−5 
(1/20, 000), respectively.
As shown in Fig. 3 and Table 4, no gene was found to be associated with schizophrenia at the genome-wide 
significance level of 2.5 × 10−6. Three genes on chromosome 19p13.2, including EVI5L (ecotropic viral integration 
site 5 like), PRR36 (proline rich 36), and LYPLA2P2 (lysophospholipase II pseudogene 2), were detected to be 
associated with schizophrenia at the suggestive significance level of 5 × 10−5. This is a consistent result across all 
the five gene-based association tests except TLC.
The 13 SNPs in the EVI5L-PRR36-LYPLA2P2 region are described in Table 5. Some of the odds ratios (ORs) of 
the minor alleles compared with the major alleles were greater than 1, whereas others were less than 1. The TLC 
test could suffer from a power loss in this situation. Hence, it was not surprising that TLC could not identify the 
association signal of this region.
Discussion
In this work, we proposed the “adaptive combination of Bayes factors” (ADABF) method, which is applicable to 
a mixture of common and rare variants and can be applied to GWAS or next-generation sequencing (NGS) data.
Chromosome 19p13.2 has been found to be associated with panic disorder39. Based on our analysis for the 
S-TOGET trio data, three genes in this region, including EVI5L, PRR36, and LYPLA2P2, were detected to be 
associated with schizophrenia at the suggestive significance level of 5 × 10−5. Four multi-marker tests including 
ADABF, ADABF1, ADA, and TK all suggest that PRR36 is the most significant gene. This gene encodes a large 
protein - Proline Rich Protein 36 (PRP36)40. The second significant gene identified by the four multi-marker tests 
is EVI5L. It is also a protein-coding gene, but its function remains unknown41. The third significant gene identi-
fied by the four tests is LYPLA2P2, which is a pseudo gene42.
The gene next to the EVI5L-PRR36-LYPLA2P2 region (7865161–7975117 base pair) is MAP2K7 
(mitogen-activated protein kinase kinase 7, also known as the “MKK7” gene, 7968665–7979363 base pair). 
Knocking out MAP2K7 results in schizophrenia-like behavioral deficits in mice43–45. A substantial effect size 
was observed for common variants in a case-control sample from the Glasgow area and a replication sample of 
Northern European descent46,47.
In our analysis of the EVI5L gene, the most prominent signal was achieved by combining the top four signifi-
cant SNPs (see Table 5, i.e., rs525420, rs1651016, rs652260, and rs555609). This was a consistent prioritization of 
SNPs across ADABF, ADABF1, and ADA. These four SNPs have not been reported to be associated with schiz-
ophrenia. As shown in these four SNPs, the ORs of the minor alleles compared with the major alleles are larger 
than 1.25 or smaller than 0.8, corresponding to one of our simulation scenarios. To detect variants with smaller 
effect sizes, the number of case-parent trios must be increased.
In this work, we used the prior in the WTCCC GWAS6 [β~N(0,W), with a variance of W = 0.22 = 0.04] as the 
prior for ADABF. To evaluate the sensitivity of our results to this choice, we also considered another prior vari-
ance, i.e., W = 0.12 = 0.01. We found that our simulation and the S-TOGET results were very stable across these 
two settings. As noted by Stephens and Balding5, W can be chosen dependently on the MAF according to prior 
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settings that are believed to best fit the underlying genetic architecture of a disease. Therefore, theoretically, we 
can develop better ways to prioritize SNPs.
With the advent of NGS technology, there has been a great interest in rare-variant association testing. 
However, both rare and common variants contribute to the etiology of complex diseases such as the Hirschsprung 
disease48, schizophrenia49, and type 2 diabetes50. Certain specialized arrays such as PsychChip were designed for 
the detection of both common and rare variants. There is a need to develop a powerful method for the joint anal-
ysis of rare and common variants. Compared with ADA2 and RC-ADA8, our ADABF method is recommended 
for its applicability to variants with a wide spectrum of MAFs. Compared with other multi-marker association 
tests such as TLC16,51, TK4,16,19,28, and VW-TOW18, our ADABF method is recommended for its robustness to the 
inclusion of neutral variants.
Figure 3. Manhattan plots of the Schizophrenia Trio Genomic Research in Taiwan (S-TOGET) data. Red lines 
indicate the genome-wide significance levels, i.e., 2.5 × 10−6 for the gene-based analyses and 5 × 10−8 for the 
single-locus analysis, respectively. Blue lines mark the suggestive significance levels, i.e., 5 × 10−5 for the gene-
based analyses and 10−6 for the single-locus analysis, respectively. The three points surpassing the suggestive 
significance threshold represent the signals of the three genes (EVI5L, PRR36, and LYPLA2P2), although only 
the most significant gene (PRR36) is labeled.
Gene Chr.
Analysis region1 
(Base pairs) #(variants)
P-value
ADABF2 ADABF12 ADA2 TK TLC
EVI5L
19
7865161–7959862 11 1.82 × 10−5 1.77 × 10−5 1.95 × 10−5 2.40 × 10−5 0.05741
PRR36 7903605–7969326 8 1.27 × 10−5 1.21 × 10−5 1.35 × 10−5 1.71 × 10−5 0.01646
LYPLA2P2 7913504–7975117 8 2.61 × 10−5 2.39 × 10−5 3.14 × 10−5 2.70 × 10−5 0.00015
Table 4. Three genes on chromosome 19p13.2 detected to be associated with schizophrenia at the suggestive 
significance level of 5 ×10−5. 1The analysis regions were based on the human GRCh37/hg19 assembly. Following 
Song et al.38, we also grouped the variants within ± 30 kb flanking regions of a gene into a multi-marker 
analysis. 2The P-values of ADABF, ADABF1, and ADA were obtained with 107 resampling replicates.
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Methods
Here, we describe the method to analyze case-parent trios, but it can be generalized to unrelated case-control 
analyses. For a variant with two alleles, i.e., M1 (the allele of interest) and M2, the TDT tests whether the M1 allele 
is transmitted to an affected child more often than the M2 allele from heterozygous parents20.
Let OR be the odds ratio of allele M1 compared with allele M2. We denote βˆ  as the MLE of log(OR). According 
to the asymptotic normality of MLE, N V( , )~β βˆ . Let b be the number of transmissions of M1 from heterozygous 
parents to the affected offspring, and let c be the number of such transmissions of M2. We then obtain 
βˆ = b clog( / ) and V b c
bc
ˆ = + . The prior distribution of the true effect sizes is assumed to be a normal distribution, 
i.e., β~N(0,W). Throughout this work, we follow the WTCCC GWAS6 to specify the prior variance, i.e., 
W = 0.22 = 0.04. The prior distribution is presented in the left column of Figure S5 of our supplementary informa-
tion. This method is designated by “ADABF.”
To evaluate the performance sensitivity of ADABF using this prior, we also specify another prior variance, i.e., 
W = 0.12 = 0.01 (right column of Figure S5). This method is designated by “ADABF1.”
According to Wakefield7,52, the BF is as follows:
β
=
+


 +



BF V
V W
W
V V W
exp
2 ( )
,
(3)
2ˆ
ˆ
ˆ
ˆ ˆ
where ˆ ˆβ V/2  is the Wald statistic. For unrelated subjects, βˆ  and Vˆ  are the MLE and its corresponding variance from 
the linear regression (continuous traits) or logistic regression (dichotomous traits) for a particular variant. The 
greater the significance of an association, the larger the ˆ ˆβ V/2  and BF. Given a fixed ˆ log(1 2) 0 18β = . = . , a larger 
Vˆ  corresponds to a lower power and a decrease in the BF, because the power is not sufficient for providing strong 
evidence supporting H1 (Figure S6). Given a fixed P-value = 0.02 (i.e., a fixed ˆ ˆβ V/
2
), the BF is small when Vˆ  is 
extremely small (Figure S7). An extremely small Vˆ  implies an extremely small βˆ
2
 given a P-value of 0.02, and thus, 
the data are unlikely under H1. Moreover, a large Vˆ  represents a low power that is not sufficient for supporting H1 
(Figure S7).
Ranking by Bayes factor vs. P-value. In this subsection, we show that the BF ranking is superior to the 
P-value ranking, in a region with a mixture of rare and common variants. We performed 200,000 simulation rep-
lications to compare the rankings of a causal variant by the BF or P-value. In each replication, one of ~150 variants 
was specified as the causal variant. As described in the simulation study, a mixture of rare and common variants 
was observed in the region (see Figure S8). The disease status (Y = 1 denotes disease) was generated according to 
the following model:
SNP1 Position
Included in the analysis for
Minor 
allele
Major 
allele MAF2 b c
Odds 
ratio3
Chi-
square 
statistic
P-value of 
single-locus 
TDT
Bayes 
factor4EVI5L PRR36 LYPLA2P2
rs12980113 7868715 V T C 0.442 583 519 1.123 3.72 0.05386 1.58
rs580984 7881030 V G A 0.483 607 484 1.254 13.87 0.000196 161.52
rs4804827 7898541 V T C 0.032 67 73 0.918 0.26 0.6121 0.70
rs652260 7900562 V C T 0.467 620 485 1.278 16.49 4.88 × 10−5 532.33
rs1651016 7904297 V V A G 0.435 620 479 1.294 18.09 2.11 × 10−5 1095.42
rs555609 7913974 V V V T C 0.450 617 483 1.277 16.32 5.34 × 10−5 492.48
rs537188 7921623 V V V A G 0.102 203 215 0.944 0.34 0.5572 0.51
rs747990 7931525 V V V A G 0.430 481 604 0.796 13.94 0.000188 167.14
rs525420 7936208 V V V G A 0.426 474 618 0.767 18.99 1.32 × 10−5 1641.32
rs483808 7957481 V V V C T 0.419 514 551 0.933 1.29 0.2569 0.53
rs533822 7959480 V V V G A 0.450 552 525 1.051 0.68 0.4107 0.40
exm1417450 7963948 V V A G 0.097 208 181 1.149 1.87 0.171 0.95
rs4804833 7970635 V A G 0.411 496 526 0.943 0.88 0.348 0.45
Table 5. The 13 SNPs in the EVI5L- PRR36- LYPLA2P2 region. 1The analysis for the EVI5L gene contained 11 
variants spanning from 7865161 to 7959862 base pair (bp), and the four SNPs shown in bold type were prioritized 
by ADABF, ADABF1, and ADA. The analysis for the PRR36 gene included 8 variants from 7903605 to 7969326 bp, 
and rs1651016, rs555609, and rs525420 were prioritized. The analysis for the LYPLA2P2 gene contained 8 variants 
from 7913504 to 7975117 bp, and rs555609 and rs525420 were prioritized. 2The minor allele frequencies (MAFs) 
were calculated according to the founder genotypes. 3The odds ratio of the minor allele compared with the major 
allele, b/c, where b is the number of transmissions of the minor allele from heterozygous parents to affected 
offspring, and c is the number of transmissions of the major allele. 4The prior distribution of log(ORs) was assumed 
to be a normal distribution with a mean of 0 and a standard deviation of 0.2.
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α β= = +logit P Y G( 1) , (4)c
where α = . . = − .log(0 05/0 95) 2 94, implying a disease prevalence of 5%. Gc was the genotype score (0, 1, or 2) 
of the causal variant, and the effect size was β = .log(1 5). In total, 200,000 replicates were performed to compare 
the ranking of a causal variant by the BF (x-axis in Fig. 4) to that by the P-value (y-axis in Fig. 4). The results 
shown in Fig. 4 and Table 6 are stratified according to the MAF of the causal variant.
Let RB and RP be the rankings of the causal variant by BF and P-value, respectively. For a region containing 
150 variants, 1 ≤ RB, RP ≤ 150. A smaller rank would be better, meaning that the causal variant would be ranked 
in priority order. The following three outcomes could be obtained: (1) the BF ranking was superior if RB < RP, 
(2) the BF ranking was identical to the P-value ranking if RB = RP, and (3) the BF ranking was inferior if RB > 
RP. According to Table 6, the mean rank of the causal variant by the BF was smaller than (or equal to) that by 
the P-value, across all ranges of causal-allele frequencies. As the MAF of the causal variant increased, the power 
to detect that causal variant also increased and both mean ranks improved. More replicates showed that the BF 
ranking outperformed the P-value ranking, across all ranges of causal-allele frequencies.
Compared with the P-value ranking, rare causal variants will benefit from the BF ranking (see the top-left plot 
of Fig. 4). This finding can be attributed to a rare causal variant generally having a larger P-value (say, 
P-value = 0.2) and a larger Vˆ  (say, Vˆ  = 0.1). As shown in Figure S9(c), its BF will be larger than that of a common 
neutral variant with the same P-value but a smaller Vˆ  (say, Vˆ  = 0.005). That is, a common variant with a 
P-value = 0.2 may actually be a neutral variant, because this large P-value is obtained from reliable information 
(smaller Vˆ). However, a rare variant with a P-value = 0.2 may still be causal, because this large P-value is obtained 
from less reliable information (larger Vˆ). Rare variants seldom have small P-values, and therefore, our previous 
ADA method2 prioritizes the rare variants with P-values smaller than 0.2. However, in a region with a mixture of 
Figure 4. Ranking by Bayes factor vs. P-value. We performed 200,000 simulations to compare the rankings 
of a causal variant using the Bayes factor (x-axis) and the P-value (y-axis). The chromosomal region included 
~150 rare or common variants, and one of these variants was specified as the causal variant. The scatter plot was 
stratified according to the MAF of the causal variant. The black line in each plot represents x = y.
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rare and common variants, a P-value threshold of 0.2 is too liberal for common variants. In this situation, it will 
be better to consider the “relative” evidence in favor of H1 (i.e., BF), instead of P-values.
Summarizing the BFs in a Chromosome Region. Let BFl be the BF of the lth variant. Denote the ordered 
BFs by BF(1) ≤ BF(2) ≤ … ≤ BF(L) for a region containing L variants. The summary score aggregating the highest 
k BFs is as follows:
∑= ≥ =
=
( )S I BF BF BF k Llog( ), 1, , , (5)k l
L
l k l
1
( )
where I(BFl ≥ BF(k)) is 1 if the lth variant is among the top k most significant variants according to BF, and is 0 oth-
erwise. Because the natural logarithm of the BF is linked to log-likelihoods, log(BF) is considered the “weight of 
evidence”10. Therefore, in Eq. (5), we summarize the association evidence provided by L variants in the region of 
interest. Because log(BF) represents the “weight of evidence”10, we do not impose any additional weight according 
to the MAF. As previously mentioned, the MAF has little relevance to association signals14,15. Disease-associated 
variants can be either rare or common. If we believe that rare variants are more likely to be non-neutral, the 
Beta(MAF;1,25) function can be used to weight the contribution of individual BFs.
Based on Eq. (5), we obtain S1, …, SL for a region containing L variants. Then, we use the efficient sequential 
resampling approach proposed by Liu et al.26 to assess the significance of the association between the region and 
a disease. The procedure is performed as follows:
 (i) We first draw B = 100 sets of βˆ0 (the L × 1 vector of point estimates under the null hypothesis) from the 
multivariate normal distribution N(0L×1,VL×L), where the (i, j)th element of VL × L is R VVi j i j, ˆ ˆ . Vˆi  and Vˆj are 
the estimated variances of βˆi and jˆβ , respectively [i, j = 1, …, L. Recall that βiˆ and Viˆ  are obtained from a 
regression model of the ith variant, such as Eq. (2)]. Yang et al.53 have shown that the correlation among the 
association statistics in a region can be well approximated by the correlation among the genotypes. 
Therefore, Ri,j is estimated from the correlation of the genotypes at the ith and jth loci. When analyzing 
case-parent trios, only the founder genotypes are used to calculate Ri,j.
 (ii) For the bth set of β0ˆ , we calculate the BFs using Eq. (3) and the summary scores using Eq. (5). Given k 
(k = 1, …, L), we compare Sk with Sk(b) (b = 1, …, B) and obtain the P-value of Sk by ∑ ≥= I S S B[ ( )]/bB k
b
k1
( ) . 
In the observed sample, we find the minimum P-value across k (k = 1, …, L), which is denoted by MinP. 
The minimum P-value of the bth resample is calculated similarly and denoted by MinP(b), b = 1, …, B. 
Finally, the adjusted P-value is ∑ ≤= I MinP MinP B[ ( )]/bB
b
1
( ) .
 (iii) If the adjusted P-value based on 100 sets of βˆ0 is smaller than 0.1, we draw 10 times more sets (i.e., 
B = 1,000) to increase the precision of the P-value. This procedure is repeated until the P-value is larger 
than B10/  or a desired precision level is reached.
The R code of our ADABF method can be downloaded from http://homepage.ntu.edu.tw/~linwy/ADABF.
html.
Competitor Methods. The ADABF test (prior variance W = 0.22 = 0.04) was compared with the ADABF1 
(prior variance W = 0.12 = 0.01) and ADA tests2. To make a fair comparison, these three tests were all performed 
using the “adaptive rank truncated product” (ARTP) method11,12. Therefore, the highest k BFs (or the smallest 
k P-values) are combined, in the observed sample and in each of the resamples, respectively. The abovemen-
tioned sequential resampling approach26 was used to assess the significance of the association between the region 
of interest and the disease, and the minimum and maximum numbers of resampling were set as 102 and 107, 
respectively.
MAF of the causal variant MAF <= 0.1% 0.1% < MAF <= 1% 1% < MAF <= 5% MAF > 5%
Mean rank of the causal variant 
by BF 17.9 16.6 10.3 4.1
Mean rank of the causal variant 
by P-value 50.3 29.8 12.0 4.1
# (replications where BF ranking 
was superior)* 46,027 33,271 13,665 1,551
# (replications where BF 
ranking was identical to P-value 
ranking)*
773 4,747 25,832 47,160
# (replications where BF ranking 
was inferior)* 3,200 11,982 10,503 1,289
Total 50,000 50,000 50,000 50,000
Table 6. Ranking of a causal variant (a smaller rank is better) in 200,000 replications. *Let RB and RP be the 
ranking of the causal variant by the BF and P-value, respectively. The following three outcomes could be 
obtained: (1) the BF ranking was superior if RB < RP; (2) the BF ranking was identical to the P-value ranking if 
RB = RP; and (3) the BF ranking was inferior if RB > RP.
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Furthermore, the TLC and TK tests were performed for comparison. These two tests were performed using the 
“rvTDT” R package (version 1.0)16 and the “SKAT” R package (version 1.2.1)4,19,28, to analyze the case-parent trios 
and unrelated subjects, respectively. To make a fair comparison, we did not assign any MAF-weighting function 
to the TLC, TK, ADABF, ADABF1, or ADA tests.
For the analysis of unrelated subjects, we also compared ADABF with VW-TOW18. VW-TOW is a test used to 
detect associations of rare and common variants, and was proposed by Sha et al.18. These authors divided the 
variants into rare (if MAF < RVT) and common (if MAF ≥ RVT), and then searched for the optimal weights for 
the two groups of variants, separately. The statistics from the two parts of the variants were then combined, and 
the P-value was calculated with permutations. This test was performed using the R code, which was downloaded 
from the authors’ website at http://www.math.mtu.edu/~shuzhang/software.html, and the number of permuta-
tions was set as 10,000. The RVT was set as n1/ 2 , where n was the sample size4. Because VW-TOW was pro-
posed for the analyses of unrelated individuals18, it was not evaluated for case-parent trio data.
Simulation Study. With the Cosi program54, we generated 100 data sets following the LD patterns in 
Europeans. Each of the 100 Cosi data sets contained 10,000 chromosomes from a 20 kilo base (kb) pairs region. 
That is, totally 100 20-kb regions were considered. On average, ~150 variants could be observed in a 20-kb region. 
The distribution of the MAFs of the variants is shown in Figure S8 in the supplementary information, which pre-
sents as an L-shaped distribution that is typical of allele frequencies55.
To evaluate the type I error rates, the disease status (Y = 1 denotes disease) was generated according to the 
following model:
logit P Y( 1) , (6)α= =
where α = −2.94. To study the power, the disease status was generated according to the following model:
logit P Y G G( 1) , (7)c d d
c
1 1 α β β= = + + +
where α = −2.94, d was the number of causal variants (d = 2 or 4), Gkc was the genotype score (0, 1, or 2) of the 
kth causal variant, and the effect sizes were β′ = ± .s log(1 5) or log(1 25)± . . β was positive or negative depending 
on whether the causal variant was deleterious or protective, respectively. When log(1 5)β = ± . , the odds ratio 
(OR) was 1.5 for a deleterious allele and . = .1/1 5 0 67 for a protective allele. When log(1 25)β = ± . , the OR was 
1.25 for a deleterious allele and . = .1/1 25 0 8 for a protective allele. The following two scenarios were evaluated:
 (1) All causal variants were deleterious and
 (2) In total, 50% of the causal variants were deleterious, and 50% of the causal variants were protective.
The following two data structures were simulated: (1) 2,000 case-parent trios and (2) 2,000 unrelated subjects, 
of which 1,000 were cases, and 1,000 were controls.
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